Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

被引：202

作者：

Pal, Sumanta K. ^{[1
]}

Rosenberg, Jonathan E. ^{[2
]}

Hoffman-Censits, Jean H. ^{[3
]}

Berger, Raanan ^{[4
]}

Quinn, David I. ^{[5
]}

Galsky, Matthew D. ^{[6
]}

Wolf, Juergen ^{[7
]}

Dittrich, Christian ^{[8
]}

Keam, Bhumsuk ^{[9
]}

Delord, Jean-Pierre ^{[10
]}

Schellens, Jan H. M. ^{[11
]}

Gravis, Gwenaelle ^{[12
]}

Medioni, Jacques ^{[13
]}

Maroto, Pablo ^{[14
]}

Sriuranpong, Virote ^{[15
,16
]}

Charoentum, Chaiyut ^{[17
]}

Burris, Howard A. ^{[18
]}

Grunwald, Viktor ^{[19
]}

Petrylak, Daniel ^{[20
]}

Vaishampayan, Ulka ^{[21
]}

Gez, Eliahu ^{[22
]}

De Giorgi, Ugo ^{[23
]}

Lee, Jae-Lyun ^{[24
]}

Voortman, Jens ^{[25
]}

Gupta, Sumati ^{[26
]}

Sharma, Sunil ^{[26
]}

Mortazavi, Amir ^{[27
]}

Vaughn, David J. ^{[28
]}

Isaacs, Randi ^{[29
]}

Parker, Katie ^{[29
]}

Chen, Xueying ^{[29
]}

Yu, Kun ^{[30
]}

Porter, Dale ^{[30
]}

Porta, Diana Graus ^{[31
]}

Bajorin, Dean F. ^{[2
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

[3] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[4] Chaim Sheba Med Ctr, Ramat Gan, Israel

[5] USC Norris Canc Ctr, Los Angeles, CA USA

[6] Mt Sinai Hosp, New York, NY 10029 USA

[7] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[8] Kaiser Franz Josef Spital, ACR ITR VIEnna, Appl Canc Res Inst Translat Res Vienna, Vienna, Austria

[9] Seoul Natl Univ Hosp, Seoul, South Korea

[10] IUCT Oncopole, Toulouse, France

[11] Netherlands Canc Inst, Amsterdam, Netherlands

[12] Inst Paoli Calmettes, Marseilles, France

[13] Hop Europeen Georges Pompidou, Paris, France

[14] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[15] Chulalongkorn Univ, Fac Med, Bangkok, Thailand

[16] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[17] Maharaj Nakorn Chiangmai Hosp, Chiang Mai, Thailand

[18] Sarah Cannon Res Inst, Nashville, TN USA

[19] Clin Hematol Hemostasis Oncol & Stem Cell Transp, Med Sch Hannover, Hannover, Germany

[20] Yale Sch Med, New Haven, CT USA

[21] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[22] Tel Aviv Sourasky Med Ctr Ichilov, Tel Aviv, Israel

[23] Inst Sci Romagnolo Studio & Cura Tumori IRST IRC, Meldola, Italy

[24] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[25] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Amsterdam, Netherlands

[26] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[27] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[28] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[29] Novartis Pharmaceut, E Hanover, NJ USA

[30] Novartis Inst BioMed Res, Cambridge, MA USA

[31] Novartis Pharma AG, Basel, Switzerland

来源：

CANCER DISCOVERY | 2018年 / 8卷 / 07期

关键词：

CISPLATIN-INELIGIBLE PATIENTS; ACQUIRED-RESISTANCE; GENETIC ALTERATIONS; BLADDER-CANCER; SINGLE-ARM; MULTICENTER; PEMBROLIZUMAB; NVP-BGJ398; MUTATIONS;

D O I：

10.1158/2159-8290.CD-18-0229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 87 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted. SIGNIFICANCE: BJG398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease. (C) 2018 AACR.

引用

页码：812 / 821

页数：10

共 50 条

[1] Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations
Pal, Sumanta K.
Rosenberg, Jonathan E.
Keam, Bhumsuk
Wolf, Juergen
Berger, Raanan
Dittrich, Christian
Hoffman-Censits, Jean H.
Quinn, David
van der Noll, Ruud
Burris, Howard A.
Galsky, Matt D.
Gravis, Gwenaelle
Lee, Jae-Lyun
Medioni, Jacques
Mortazavi, Amir
Maroto, Pablo
Parker, Katie
Chen, Xueying
Isaacs, Randi
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma
Lyou, Yung
Grivas, Petros
Rosenberg, Jonathan E.
Hoffman-Censits, Jean
Quinn, David, I
Petrylak, Daniel P.
Galsky, Matthew
Vaishampayan, Ulka
De Giorgi, Ugo
Gupta, Sumati
Burris, Howard
Rearden, Jessica
Li, Ai
Wang, Hao
Reyes, Maribel
Moran, Susan
Daneshmand, Siamak
Bajorin, Dean
Pal, Sumanta K.
EUROPEAN UROLOGY, 2020, 78 (06) : 916 - 924
[3] Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC)
Grivas, Petros
Daneshmand, Siamak
Makarov, Vladimir
Bellmunt, Joaquim
Sridhar, Srikala S.
Sonpavde, Guru P.
Cole, Suzanne
Tripathi, Abhishek
Faltas, Bishoy Morris
Lerner, Seth P.
Fleming, Mark T.
Loriot, Yohann
Meeks, Joshua J.
Master, Viraj A.
Davis, Kimberlee
Van Veenhuyzen, David Friedrich
Afifi, Shugufa
Pal, Sumanta Kumar
Gupta, Shilpa
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model
Schmidt, Katharina
Moser, Christian
Hellerbrand, Claus
Zieker, Derek
Wagner, Christine
Redekopf, Julia
Schlitt, Hans J.
Geissler, Edward K.
Lang, Sven A.
ANTICANCER RESEARCH, 2015, 35 (12) : 6655 - 6665
[5] Mechanisms of acquired resistance to the fibroblast growth factor receptor (FGFR) inhibitor BGJ398 in FGFR driven bladder cancer
Hodgson-Garms, M.
Mariadason, J.
Weickhardt, A.
ANNALS OF ONCOLOGY, 2016, 27
[6] INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY
Lassman, A. B.
Sepulveda-Sanchez, J. M.
Cloughesy, T.
Gil-Gil, J. M.
Puduvalli, V. K.
Raizer, J.
De Vos, F. Y.
Wen, P. Y.
Butowski, N.
Clement, P.
Groves, M. D.
Belda-Iniesta, C.
Steward, K.
Moran, S.
Ye, Y.
Roth, P.
NEURO-ONCOLOGY, 2019, 21 : 21 - 22
[7] INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY
Lassman, Andrew
Sepulveda-Sanchez, Juan
Cloughesy, Timothy
Gil-Gil, Juan
Puduvalli, Vinay
Raizer, Jeffrey
De Vos, Filip
Wen, Patrick
Butowski, Nicholas
Clement, Paul
Groves, Morris
Belda-Iniesta, Cristobal
Steward, Keith
Rowsey, Steven
Ye, Yining
Roth, Patrick
NEURO-ONCOLOGY, 2019, 21 : 20 - 20
[8] Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC)
Lyou, Yung
Grivas, Petros
Rosenberg, Jonathan E.
Hoffman-Censits, Jean H.
Quinn, David I.
Petrylak, Daniel Peter
Galsky, Matt D.
Vaishampayan, Ulka N.
De Giorgi, Ugo
Gupta, Sumati
Burris, Howard A.
Rearden, Jessica
Ye, Yining
Wang, Hao
Moran, Susan
Daneshmand, Siamak
Bajorin, Dean F.
Pal, Sumanta K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[9] ACQUIRED RESISTANCE TO THE FIBROBLAST GROWTH FACTOR RECEPTOR ( FGFR) INHIBITOR BGJ398 IN FGFR3 DRIVEN BLADDER CANCER IS OVERCOME BY CO-TARGETING THE RAPIDLY INDUCED PAXL OR PERBB3 PATHWAYS
Weickhardt, Andrew
Lau, David
Lavis, Austen
Garms, Margeaux
Mariadason, John
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 63 - 63
[10] Infigratinib Fibroblast growth factor receptor (FGFR) 1-3 inhibitor Treatment of cholangiocarcinoma Treatment of urothelial carcinoma
Katoh, Masuko
Katoh, Masaru
DRUGS OF THE FUTURE, 2020, 45 (01) : 5 - 11

← 1 2 3 4 5 →